The Globe and Mail Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account Getting audio file ... This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer Inside the Market’s roundup of some of today’s key analyst actions CIBC downgraded Organigram Holdings Inc. (OGI-T) to an “underperformer” rating - the equivalent of a sell recommendation - from “neutral”, and was among several brokers that slashed price targets on the cannabis company following disappointing quarterly results. Organigram said Tuesday it had a net loss of $66.4 million (Canadian) in its fiscal second quarter to Feb. 28, wider than the loss of $6.8 million posted in the year-earlier quarter. Revenue fell to $14.6 million from $23.2 million, missing the Street consensus of $19.1 million. Revenue was hurt by missed sales opportunities as a “significant number” of staff had to isolate amid certain employees testing positive for COVID-19.